| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
SARS-CoV[1]
SSAA09E3 targets the fusion process of SARS-CoV, preventing the viral membrane from fusing with the host cellular membrane. The compound likely interacts with the viral spike protein or host cell membrane components to block fusion. This mechanism is distinct from other antiviral approaches, making it a valuable tool for studying viral entry. |
|---|---|
| ln Vitro |
SSAA09E3 prevents the fusion of the viral membrane with the host cell membrane, which prevents the entry of the virus[1]. Later viral entrance stages are inhibited by SSAA09E3[2].
In vitro, SSAA09E3 inhibits SARS/HIV pseudotyped virus entry into HEK293T cells with an EC50 of 9.7 μM. It also inhibits SARS-CoV infection of Vero cells with an EC50 of 0.15 μM. These activities have been demonstrated in cell-based assays using pseudotyped and live viruses, confirming its potent antiviral activity. |
| ln Vivo |
In vivo data for SSAA09E3 are limited. As a viral entry inhibitor, it is expected to have potential for treating SARS-CoV infections. However, specific in vivo studies have not been detailed in the available literature. Further research is needed to evaluate its efficacy and safety in animal models.
|
| Enzyme Assay |
The in vitro assay for SSAA09E3 typically involves measuring its ability to inhibit viral entry. This is done using pseudotyped viruses, such as SARS/HIV, in HEK293T cells. The compound's EC50 is determined by measuring the reduction in viral entry. Live-virus assays using Vero cells and SARS-CoV are also used. These assays confirm its antiviral activity.
|
| Cell Assay |
Cellular assays for SSAA09E3 are performed using HEK293T cells and Vero cells. Cells are infected with pseudotyped or live virus in the presence of the compound, and viral entry or infection is measured. The EC50 values are determined from these dose-response experiments.
|
| Animal Protocol |
In vivo animal protocols for SSAA09E3 are not available in the literature. As a SARS-CoV entry inhibitor, it would typically be evaluated in mouse models of SARS-CoV infection. However, such studies have not been reported. The compound is currently used primarily for in vitro research.
|
| ADME/Pharmacokinetics |
Pharmacokinetic (PK) properties of SSAA09E3 have not been characterized. It is a small molecule with a molecular weight of 327.33. The compound is typically dissolved in DMSO for in vitro studies. Further studies are needed to determine its ADME profile.
|
| Toxicity/Toxicokinetics |
Toxicity data for SSAA09E3 are limited. As a viral entry inhibitor, it may have a favorable safety profile, but comprehensive toxicological studies are needed. The compound is intended for research use only and is not approved for human therapeutic use.
|
| References | |
| Additional Infomation |
SSAA09E3 is a SARS-CoV entry inhibitor that blocks viral membrane fusion. It shows potent activity against SARS-CoV in cell-based assays. The compound is used as a research tool for studying viral entry mechanisms and is not currently in clinical trials.
|
| Molecular Formula |
C21H13NO3
|
|---|---|
| Molecular Weight |
327.33
|
| Exact Mass |
327.09
|
| CAS # |
52869-18-8
|
| Related CAS # |
883944-52-3 (SSAA09E2);
|
| PubChem CID |
570342
|
| Appearance |
Light brown to brown solid powder
|
| LogP |
4.098
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
25
|
| Complexity |
551
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
SIGATAYQAZTAOH-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C21H13NO3/c23-19-15-8-4-5-9-16(15)20(24)18-12-14(10-11-17(18)19)22-21(25)13-6-2-1-3-7-13/h1-12H,(H,22,25)
|
| Chemical Name |
N-(9,10-dioxoanthracen-2-yl)benzamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : 33.33 mg/mL (101.82 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.0550 mL | 15.2751 mL | 30.5502 mL | |
| 5 mM | 0.6110 mL | 3.0550 mL | 6.1100 mL | |
| 10 mM | 0.3055 mL | 1.5275 mL | 3.0550 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
